Taxa de descontinuação da terapia antirretroviral dupla com dolutegravir mais lamivudina em pessoas vivendo com HIV: uma revisão sistemática
DOI:
https://doi.org/10.33448/rsd-v11i12.34758Palavras-chave:
Terapia Antirretroviral; Dolutegravir; Lamivudina; HIV.Resumo
As terapias antirretrovirais são utilizadas como forma de melhorar a expectativa de vida das pessoas vivendo com HIV. Com a redução dos efeitos adversos, a terapia dupla com dolutegravir (DTG) mais lamivudina (3TC) vêm se mostrando uma opção viável. No entanto, mesmo apresentando uma eficácia similar à terapia tripla, ainda há a ausência de enfoque nas taxas de descontinuação do tratamento. Por este motivo, o objetivo com esse trabalho foi avaliar a taxa de descontinuação da terapia antirretroviral dupla com DTG mais 3TC em pessoas vivendo com HIV. Foi realizada uma revisão sistemática nas bases de dados PubMed, SciElo e Scopus, a partir da seleção de estudos de coorte que relataram a taxa de descontinuação com uso da terapia dupla com DTG mais 3TC. Foram selecionados 14 artigos, oito estudos retrospectivos e seis estudos prospectivos. A população foi composta por 2.666 indivíduos, com idade média de 50,4 anos, sendo 75,2% do sexo masculino. A taxa de descontinuação da terapia dupla com DTG mais 3TC descrita nos estudos variou de 0,0% a 22,4%. Um total de 364 indivíduos descontinuaram a terapia dupla com DTG mais 3TC, sendo a taxa de descontinuação observada de 13,7% (IC95% 13,0-14,4%). Os principais motivos para descontinuação foram eventos neuropsiquiátricos (19,5%), falha virológica (10,7%) e toxicidade gastrointestinal (8,8%). Mesmo com os benefícios fornecidos pela terapia dupla, alguns fatores ainda contribuem para a descontinuação do tratamento, sendo possível observar ainda uma alta taxa de descontinuação do tratamento utilizando a terapia dupla de DTG mais 3TC. Incluir o resumo.
Referências
Arribas, J. R., Girard, P. M., Landman, R., Pich, J., Mallolas, J., Martínez-Rebollar, M., Zamora, F. X., Estrada, V., Crespo, M., Podzamczer, D., Portilla, J., Dronda, F., Iribarren, J. A., Domingo, P., Pulido, F., Montero, M., Knobel, H., Cabié, A., Weiss, L., Gatell, J. M., … OLE/RIS-EST13 Study Group (2015). Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. The Lancet. Infectious diseases, 15(7), 785–792. https://doi.org/10.1016/S1473-3099(15)00096-1
Back D. (2017). 2-Drug regimens in HIV treatment: pharmacological considerations. Germs, 7(3), 113–114. https://doi.org/10.18683/germs.2017.1115
Baldin, G., Ciccullo, A., Rusconi, S., Madeddu, G., Sterrantino, G., Freedman, A., Giacometti, A., Celani, L., Latini, A., Rossetti, B., Cossu, M. V., Giacomelli, A., Lagi, F., Capetti, A., & Di Giambenedetto, S. (2019). Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study. Le infezioni in medicina, 27(4), 410–414.
Baldin, G., Ciccullo, A., Rusconi, S., Capetti, A., Sterrantino, G., Colafigli, M., d'Ettorre, G., Giacometti, A., Cossu, M. V., Borghetti, A., Gennari, W., Mussini, C., Borghi, V., & Di Giambenedetto, S. (2019). Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. International journal of antimicrobial agents, 54(6), 728–734. https://doi.org/10.1016/j.ijantimicag.2019.09.002
Baldin, G., Ciccullo, A., Lombardi, F., D'Angelillo, A., Dusina, A., Emiliozzi, A., Farinacci, D., Moschese, D., Picarelli, C., Borghetti, A., & Di Giambenedetto, S. (2021). Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice. AIDS research and human retroviruses, 37(6), 429–432. https://doi.org/10.1089/AID.2020.0219
Barlow-Mosha, L., Musiime, V., Davies, M. A., Prendergast, A. J., Musoke, P., Siberry, G., & Penazzato, M. (2017). Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation. Journal of the International AIDS Society, 20(1), 21552. https://doi.org/10.7448/IAS.20.1.21552
Barr, D., Odetoyinbo, M., Mworeko, L., & Greenberg, J. (2015). The leadership of communities in HIV service delivery. AIDS (London, England), 29 Suppl 2, S121–S127. https://doi.org/10.1097/QAD.0000000000000717
Berrien, V. M., Salazar, J. C., Reynolds, E., McKay, K., & HIV Medication Adherence Intervention Group (2004). Adherence to antiretroviral therapy in HIV-infected pediatric patients improves with home-based intensive nursing intervention. AIDS patient care and STDs, 18(6), 355–363. https://doi.org/10.1089/1087291041444078
Borghetti, A., Baldin, G., Ciccullo, A., Gagliardini, R., D'Avino, A., Mondi, A., Ciccarelli, N., Lamonica, S., Fanti, I., Trecarichi, E., Fabbiani, M., Cauda, R., De Luca, A., & Di Giambenedetto, S. (2016). Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy. The Journal of antimicrobial chemotherapy, 71(8), 2359–2361. https://doi.org/10.1093/jac/dkw147
Borghetti, A., Baldin, G., Lombardi, F., Ciccullo, A., Capetti, A., Rusconi, S., Sterrantino, G., Latini, A., Cossu, M. V., Gagliardini, R., De Luca, A., & Di Giambenedetto, S. (2018). Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV medicine, 10.1111/hiv.12611. Advance online publication. https://doi.org/10.1111/hiv.12611
Borghetti, A., Lombardi, F., Gagliardini, R., Baldin, G., Ciccullo, A., Moschese, D., Emiliozzi, A., Belmonti, S., Lamonica, S., Montagnani, F., Visconti, E., De Luca, A., & Di Giambenedetto, S. (2019). Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. BMC infectious diseases, 19(1), 59. https://doi.org/10.1186/s12879-018-3666-8
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., Hagins, D., Felizarta, F., Madruga, J., Reuter, T., Newman, T., Small, C. B., Lombaard, J., Grinsztejn, B., Dorey, D., Underwood, M., … extended SAILING Study Team (2013). Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet (London, England), 382(9893), 700–708. https://doi.org/10.1016/S0140-6736(13)61221-0
Cahn, P., Madero, J. S., Arribas, J. R., Antinori, A., Ortiz, R., Clarke, A. E., Hung, C. C., Rockstroh, J. K., Girard, P. M., Sievers, J., Man, C. Y., Urbaityte, R., Brandon, D. J., Underwood, M., Tenorio, A. R., Pappa, K. A., Wynne, B., Gartland, M., Aboud, M., van Wyk, J., … Smith, K. Y. (2020). Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. Journal of acquired immune deficiency syndromes (1999), 83(3), 310–318. https://doi.org/10.1097/QAI.0000000000002275
Calza, L., Colangeli, V., Borderi, M., Testi, D., Granozzi, B., Bon, I., Re, M. C., & Viale, P. (2020). Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy. The Journal of antimicrobial chemotherapy, 75(11), 3327–3333. https://doi.org/10.1093/jac/dkaa319
Ciccullo, A., Baldin, G., Capetti, A., Rusconi, S., Sterrantino, G., d'Ettorre, G., Colafigli, M., Modica, S., Lagi, F., Giacomelli, A., Cossu, M. V., Restelli, S., De Luca, A., & Di Giambenedetto, S. (2019). A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients. Antiviral therapy, 24(1), 63–67. https://doi.org/10.3851/IMP3270
da Cunha, J., Maselli, L. M., Stern, A. C., Spada, C., & Bydlowski, S. P. (2015). Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs. World journal of virology, 4(2), 56–77. https://doi.org/10.5501/wjv.v4.i2.56
Deeks, S. G., Overbaugh, J., Phillips, A., & Buchbinder, S. (2015). HIV infection. Nature reviews. Disease primers, 1, 15035. https://doi.org/10.1038/nrdp.2015.35
Department of Health and Human Services (DHHS). (2019). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf
Di Giambenedetto, S., Fabbiani, M., Quiros Roldan, E., Latini, A., D'Ettorre, G., Antinori, A., Castagna, A., Orofino, G., Francisci, D., Chinello, P., Madeddu, G., Grima, P., Rusconi, S., Di Pietro, M., Mondi, A., Ciccarelli, N., Borghetti, A., Focà, E., Colafigli, M., De Luca, A., … Atlas-M Study Group (2017). Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). The Journal of antimicrobial chemotherapy, 72(4), 1163–1171. https://doi.org/10.1093/jac/dkw557
Drukker, M., Weltens, I., van Hooijdonk, C., Vandenberk, E., & Bak, M. (2021). Development of a Methodological Quality Criteria List for Observational Studies: The Observational Study Quality Evaluation. Frontiers in research metrics and analytics, 6, 675071. https://doi.org/10.3389/frma.2021.675071
Elliot, E. R., Wang, X., Singh, S., Simmons, B., Vera, J. H., Miller, R. F., Fitzpatrick, C., Moyle, G., McClure, M., & Boffito, M. (2019). Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 68(1), 87–95. https://doi.org/10.1093/cid/ciy426
Fabbiani, M., Di Giambenedetto, S., Poli, A., Borghetti, A., Castagna, A., Mondi, A., Galizzi, N., Maillard, M., Gori, A., Cauda, R., De Luca, A., & Gianotti, N. (2016). Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. The Journal of infection, 73(6), 619–623. https://doi.org/10.1016/j.jinf.2016.08.011
Fabbiani, M., Gagliardini, R., Ciccarelli, N., Quiros Roldan, E., Latini, A., d'Ettorre, G., Antinori, A., Castagna, A., Orofino, G., Francisci, D., Chinello, P., Madeddu, G., Grima, P., Rusconi, S., Del Pin, B., Lombardi, F., D'Avino, A., Focà, E., Colafigli, M., Cauda, R., … ATLAS-M Study Group (2018). Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. The Journal of antimicrobial chemotherapy, 73(7), 1955–1964. https://doi.org/10.1093/jac/dky123
Fabbiani, M., Rossetti, B., Ciccullo, A., Oreni, L., Lagi, F., Celani, L., Colafigli, M., De Vito, A., Mazzitelli, M., Dusina, A., Durante, M., Montagnani, F., Rusconi, S., Capetti, A., Sterrantino, G., D'Ettorre, G., Di Giambenedetto, S., & ODOACRE Study Group (2021). Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort. HIV medicine, 22(9), 843–853. https://doi.org/10.1111/hiv.13146
Food and Drug Administration - FDA (2019). DOVATO - Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211994s000lbl.pdf.
Galizzi, N., Poli, A., Galli, L., Muccini, C., Mastrangelo, A., Dell'Acqua, R., Maillard, M., Bossolasco, S., Cinque, P., Lazzarin, A., Castagna, A., & Gianotti, N. (2020). Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. International journal of antimicrobial agents, 55(3), 105893. https://doi.org/10.1016/j.ijantimicag.2020.105893
Hidalgo-Tenorio, C., Cortés, L. L., Gutiérrez, A., Santos, J., Omar, M., Gálvez, C., Sequera, S., Jesús, S. E., Téllez, F., Fernández, E., García, C., & Pasquau, J. (2019). DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients. Medicine, 98(32), e16813. https://doi.org/10.1097/MD.0000000000016813
Hidalgo-Tenorio, C., Pasquau, J., Vinuesa, D., Ferra, S., Terrón, A., SanJoaquín, I., Payeras, A., Martínez, O. J., López-Ruz, M. Á., Omar, M., de la Torre-Lima, J., López-Lirola, A., Palomares, J., Blanco, J. R., Montero, M., & García-Vallecillos, C. (2022). DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks). Viruses, 14(3), 524. https://doi.org/10.3390/v14030524
Hoffmann, C., Welz, T., Sabranski, M., Kolb, M., Wolf, E., Stellbrink, H. J., & Wyen, C. (2017). Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV medicine, 18(1), 56–63. https://doi.org/10.1111/hiv.12468
Joint United Nations Programme on HIV/Aids - UNAIDS (2014). UNAIDS 90-90-90: an ambitious treatment target to help end the AIDS epidemic.
Joint United Nations Programme on HIV/Aids - UNAIDS (2022). Global HIV & AIDS statistics — Fact sheet. ttps://www.unaids.org/en/resources/fact-sheet
Kumar, S., & Samaras, K. (2018). The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Frontiers in endocrinology, 9, 705. https://doi.org/10.3389/fendo.2018.00705
Latini, A., Fabbiani, M., Borghi, V., Sterrantino, G., Giannetti, A., Lorenzini, P., Loiacono, L., Ammassari, A., Bellagamba, R., Colafigli, M., D'Ettorre, G., Di Giambenedetto, S., Antinori, A., & Zaccarelli, M. (2016). Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC infectious diseases, 16(1), 401. https://doi.org/10.1186/s12879-016-1703-z
Luque-Fernandez, M. A., Van Cutsem, G., Goemaere, E., Hilderbrand, K., Schomaker, M., Mantangana, N., Mathee, S., Dubula, V., Ford, N., Hernán, M. A., & Boulle, A. (2013). Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PloS one, 8(2), e56088. https://doi.org/10.1371/journal.pone.0056088
Maggiolo, F., Gulminetti, R., Pagnucco, L., Digaetano, M., Benatti, S., Valenti, D., Callegaro, A., Ripamonti, D., & Mussini, C. (2017). Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC infectious diseases, 17(1), 215. https://doi.org/10.1186/s12879-017-2311-2
Mendoza, I., Lázaro, A., & Torralba, M. (2022). Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults. The Annals of pharmacotherapy, 56(4), 412–421. https://doi.org/10.1177/10600280211034176
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097
Mondi, A., Fabbiani, M., Ciccarelli, N., Colafigli, M., D'Avino, A., Borghetti, A., Gagliardini, R., Cauda, R., De Luca, A., & Di Giambenedetto, S. (2015). Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. The Journal of antimicrobial chemotherapy, 70(6), 1843–1849. https://doi.org/10.1093/jac/dkv037
Neyeloff, J. L., Fuchs, S. C., & Moreira, L. B. (2012). Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC research notes, 5, 52. https://doi.org/10.1186/1756-0500-5-52
National Health Service - NHS (2022). Overview - HIV and AIDS. https://www.nhs.uk/conditions/hiv-and-aids/
Patel, R., Evitt, L., Mariolis, I., Di Giambenedetto, S., d'Arminio Monforte, A., Casado, J., Cabello Úbeda, A., Hocqueloux, L., Allavena, C., Barber, T., Jha, D., Kumar, R., Kamath, R. D., Vincent, T., van Wyk, J., & Koteff, J. (2021). HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review. Infectious diseases and therapy, 10(4), 2051–2070. https://doi.org/10.1007/s40121-021-00522-7
Peñafiel, J., de Lazzari, E., Padilla, M., Rojas, J., Gonzalez-Cordon, A., Blanco, J. L., Blanch, J., Marcos, M. A., Lonca, M., Martinez-Rebollar, M., Laguno, M., Tricas, A., Rodriguez, A., Mallolas, J., Gatell, J. M., & Martinez, E. (2017). Tolerability of integrase inhibitors in a real-life setting. The Journal of antimicrobial chemotherapy, 72(6), 1752–1759. https://doi.org/10.1093/jac/dkx053
Perez-Molina, J. A., Rubio, R., Rivero, A., Pasquau, J., Suárez-Lozano, I., Riera, M., Estébanez, M., Palacios, R., Sanz-Moreno, J., Troya, J., Mariño, A., Antela, A., Navarro, J., Esteban, H., Moreno, S., & GeSIDA 7011 Study Group (2017). Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). The Journal of antimicrobial chemotherapy, 72(1), 246–253. https://doi.org/10.1093/jac/dkw379
Pulido, F., Ribera, E., Lagarde, M., Pérez-Valero, I., Palacios, R., Iribarren, J. A., Payeras, A., Domingo, P., Sanz, J., Cervero, M., Curran, A., Rodríguez-Gómez, F. J., Téllez, M. J., Ryan, P., Barrufet, P., Knobel, H., Rivero, A., Alejos, B., Yllescas, M., Arribas, J. R., … DUAL-GESIDA-8014-RIS-EST45 Study Group (2017). Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 65(12), 2112–2118. https://doi.org/10.1093/cid/cix734
Punekar, Y. S., Parks, D., Joshi, M., Kaur, S., Evitt, L., Chounta, V., Radford, M., Jha, D., Ferrante, S., Sharma, S., Van Wyk, J., & de Ruiter, A. (2021). Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence. HIV medicine, 22(6), 423–433. https://doi.org/10.1111/hiv.13050
Raffi, F., Rachlis, A., Stellbrink, H. J., Hardy, W. D., Torti, C., Orkin, C., Bloch, M., Podzamczer, D., Pokrovsky, V., Pulido, F., Almond, S., Margolis, D., Brennan, C., Min, S., & SPRING-2 Study Group (2013). Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet (London, England), 381(9868), 735–743. https://doi.org/10.1016/S0140-6736(12)61853-4
Romanelli, R. M., Pinto, J. A., Melo, L. J., Vasconcelos, M. A., & Pereira, R. (2006). Effectiveness of dual and triple antiretroviral therapy in the treatment of HIV-infected children. Jornal de pediatria, 82(4), 260–265. https://doi.org/10.2223/JPED.1505
Salter, M. L., Lau, B., Go, V. F., Mehta, S. H., & Kirk, G. D. (2011). HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 53(12), 1256–1264. https://doi.org/10.1093/cid/cir673
Soriano, V., Fernandez-Montero, J. V., Benitez-Gutierrez, L., Mendoza, C., Arias, A., Barreiro, P., Peña, J. M., & Labarga, P. (2017). Dual antiretroviral therapy for HIV infection. Expert opinion on drug safety, 16(8), 923–932. https://doi.org/10.1080/14740338.2017.1343300
Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., Moher, D., Becker, B. J., Sipe, T. A., & Thacker, S. B. (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA, 283(15), 2008–2012. https://doi.org/10.1001/jama.283.15.2008
Tan, M., Johnston, S., Nicholls, J., & Gompels, M. (2019). Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients?.HIV medicine, 20(9), 634–637. https://doi.org/10.1111/hiv.12781
Teira, R., Diaz-Cuervo, H., Aragão, F., Castaño, M., Romero, A., Roca, B., Montero, M., Galindo, M. J., Muñoz-Sánchez, M. J., Espinosa, N., Peraire, J., Martínez, E., de la Fuente, B., Domingo, P., Deig, E., Merino, M. D., Geijo, P., Estrada, V., Sepúlveda, M. A., García, J., … Currán, A. (2022). Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort. Infectious diseases and therapy, 11(3), 1177–1192. https://doi.org/10.1007/s40121-022-00630-y
Wamalwa, D. C., Farquhar, C., Obimbo, E. M., Selig, S., Mbori-Ngacha, D. A., Richardson, B. A., Overbaugh, J., Egondi, T., Inwani, I., & John-Stewart, G. (2009). Medication diaries do not improve outcomes with highly active antiretroviral therapy in Kenyan children: a randomized clinical trial. Journal of the International AIDS Society, 12, 8. https://doi.org/10.1186/1758-2652-12-8
World Health Organization - WHO (2022). Health topics. HIV/AIDS.https://www.who.int/health-topics/hiv-aids#tab=tab_1
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2022 Marina Rezende da Silveira; Gabriel de Souza-Silva; Jullye Campos Mendes; Simone Furtado dos Santos; Clessius Ribeiro Ribeiro de Souza; Micheline Rosa Silveira
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Autores que publicam nesta revista concordam com os seguintes termos:
1) Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.
2) Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
3) Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado.
